Literature DB >> 21031624

Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β-induced neurite atrophy.

Takuya Urano1, Chihiro Tohda.   

Abstract

Essential therapeutic drugs for Alzheimer's disease (AD) have not been developed. Since the neuritic atrophy leading to synaptic losses is one of the critical causes of memory impairment in AD, the effects of several constituents in tonic herbal medicines on neuritic atrophy and memory deficits have been studied. The present study investigated the effects of icariin, a main constituent in Epimedii Herba, a well known tonic crude drug, in an in vitro AD model and transgenic mouse AD model (5xFAD). Amyloid β(1-42)-induced atrophies of axons and dendrites were restored by post-treatment with icariin in rat cortical neurons. Administration of icariin for 8 days (p.o.) improved spatial memory impairment in 5xFAD mice. These novel findings suggest that icariin may improve memory dysfunction in AD and have a potential to extend neurites even when amyloid β-induced neurite atrophy has already occurred.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21031624     DOI: 10.1002/ptr.3183

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  32 in total

1.  Icariin Ameliorates Amyloid Pathologies by Maintaining Homeostasis of Autophagic Systems in Aβ1-42-Injected Rats.

Authors:  Xia Jiang; Lin-Lin Chen; Zhou Lan; Fan Xiong; Xiang Xu; Yang-Yang Yin; Ping Li; Ping Wang
Journal:  Neurochem Res       Date:  2019-10-15       Impact factor: 3.996

2.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

3.  Icariin Improves Cognitive Impairment after Traumatic Brain Injury by Enhancing Hippocampal Acetylation.

Authors:  Zi-Gang Zhang; Xin Wang; Jin-Hai Zai; Cai-Hua Sun; Bing-Chun Yan
Journal:  Chin J Integr Med       Date:  2018-01-09       Impact factor: 1.978

4.  Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation.

Authors:  Lan Zhang; Cong Shen; Jin Chu; Ying Liu; Yali Li; Li Zhang; Lin Li
Journal:  Age (Dordr)       Date:  2015-07-14

5.  Phenotypic assays for β-amyloid in mouse embryonic stem cell-derived neurons.

Authors:  Laura Beth J McIntire; Natalie Landman; Min Suk Kang; Gina M Finan; Jeremy C Hwang; Ann Z Moore; Lydia S Park; Chyuan-Sheng Lin; Tae-Wan Kim
Journal:  Chem Biol       Date:  2013-07-25

6.  Neuroprotective Effects of Icariin on Brain Metabolism, Mitochondrial Functions, and Cognition in Triple-Transgenic Alzheimer's Disease Mice.

Authors:  Yi-Jing Chen; Hai-Yang Zheng; Xiu-Xian Huang; Shuang-Xue Han; Dong-Sheng Zhang; Jia-Zuan Ni; Xiao-Yang He
Journal:  CNS Neurosci Ther       Date:  2015-11-20       Impact factor: 5.243

Review 7.  EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.

Authors:  Leon M Tai; Deebika Balu; Evangelina Avila-Munoz; Laila Abdullah; Riya Thomas; Nicole Collins; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  J Lipid Res       Date:  2017-04-07       Impact factor: 5.922

8.  Icariin protects rat cardiac H9c2 cells from apoptosis by inhibiting endoplasmic reticulum stress.

Authors:  Qiufang Zhang; Hongliang Li; Shanshan Wang; Ming Liu; Yibin Feng; Xuanbin Wang
Journal:  Int J Mol Sci       Date:  2013-08-30       Impact factor: 5.923

9.  Epimedium koreanum Extract and Its Constituent Icariin Improve Motor Dysfunction in Spinal Cord Injury.

Authors:  Chihiro Tohda; Aiko Nagata
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-23       Impact factor: 2.629

10.  Diosgenin is an exogenous activator of 1,25D₃-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice.

Authors:  Chihiro Tohda; Takuya Urano; Masahito Umezaki; Ilka Nemere; Tomoharu Kuboyama
Journal:  Sci Rep       Date:  2012-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.